Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143507
Full metadata record
DC FieldValueLanguage
dc.creatorParreira, E
dc.creatorLuzeiro, I
dc.creatorPereira-Monteiro, J
dc.date.accessioned2022-08-29T14:35:13Z-
dc.date.available2022-08-29T14:35:13Z-
dc.date.issued2020
dc.identifier.issn0870-399X
dc.identifier.urihttps://hdl.handle.net/10216/143507-
dc.description.abstractMigraine is highly prevalent and carries a significant personal, social and economic burden. It is the second cause of disability (years living with disability) worldwide and the first cause under 50 years of age. Chronic migraine (occurring for more than 15 days a month) and refractory migraine (treatment resistant), especially when there is also analgesic overuse, are the most disabling forms of migraine. These three disorders (chronic migraine, refractory migraine and medication overuse headache) are particularly difficult to treat. This article reviews their epidemiology, clinical presentation, diagnostic criteria, risk factors, comorbidities and social and personal impact. The therapeutic options available are discussed and focused on a multidisciplinary approach, non-pharmacological interventions treatment of comorbidities and avoiding analgesic overuse. Prophylactic treatments are mandatory and include the oral prophylactic treatments (topiramate), botulinum toxin type A and the novel monoclonal antibodies against calcitonin gene related peptide or its receptor, which are the first migraine preventive medicines developed specifically to target migraine pathogenesis. In refractory cases, multiple therapies are required including neurostimulation.
dc.language.isopor
dc.publisherOrdem dos Médicos
dc.relation.ispartofActa Medica Portuguesa, vol.33(11), p. 753-760
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHeadache Disorders, Secondary/chemically induced
dc.subjectMigraine Disorders/diagnosis
dc.subjectMigraine Disorders/drug therapy
dc.subject.meshAntibodies, Monoclonal / therapeutic use
dc.subject.meshAnticonvulsants / administration & dosage
dc.subject.meshAnticonvulsants / therapeutic use
dc.subject.meshBotulinum Toxins, Type A / therapeutic use
dc.subject.meshChronic Disease
dc.subject.meshHeadache
dc.subject.meshHeadache Disorders, Secondary / chemically induced
dc.subject.meshHeadache Disorders, Secondary / drug therapy
dc.subject.meshHeadache Disorders, Secondary / prevention & control
dc.subject.meshHumans
dc.subject.meshMigraine Disorders / diagnosis
dc.subject.meshMigraine Disorders / drug therapy
dc.subject.meshMigraine Disorders / prevention & control
dc.subject.meshNeuromuscular Agents / therapeutic use
dc.subject.meshTopiramate / administration & dosage
dc.subject.meshTopiramate / therapeutic use
dc.titleChronic and Refractory Migraine: How to Diagnose and Treat
dc.typeArtigo em Revista Científica Nacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.20344/amp.12004
dc.relation.publisherversionhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/12004
Appears in Collections:I3S - Artigo em Revista Científica Nacional

Files in This Item:
File Description SizeFormat 
10.20344-amp.12004.pdf410.9 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons